Andere talen BeyondSpring Inc.

Aandelen

BYSI

KYG108301006

Biotechnologie & Medisch Onderzoek

Geschatte realtime Cboe BZX Andere beurzen 19:24:12 24-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,550 ^USD	-6,93%		-22,35%	+61,96%

03/06	BeyondSpring Inc. presenteert gegevens over de werkzaamheid en veiligheid van een fase 2-studie met pembrolizumab plus plinabulin/docetaxel bij gemetastaseerde NSCLC na progressie bij eerstelijns immuuncheckpointremmers tijdens de ASCO-jaarvergadering van 2025.	CI
12/05	BeyondSpring Inc. rapporteert resultaten over het eerste kwartaal eindigend op 31 maart 2025	CI

Andere talen

BeyondSpring Inc.(NasdaqCM:BYSI) added to S&P TMI Index	23/06
BeyondSpring Inc. Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting	03/06
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting	03/06
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting	28/05
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update	12/05
BeyondSpring Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	12/05
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	27/03
BeyondSpring Files 2024 Annual Report on Form 10-K	27/03
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones	27/03
BeyondSpring : 2024 Full Year Financial Report	27/03
SEED Therapeutics Appoints Eisai Co., Ltd.'s Dr. Yoshiharu Mizui to Board of Directors	29/01
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies	28/01
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors	28/01
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin, Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors	12/11
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting	11/11
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting	11/11
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024	16-09-24
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024	16-09-24
BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024	16-09-24
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine	10-09-24
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin	03-09-24
BeyondSpring : 2024 Second Quarter Financial Report	29-08-24
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	29-08-24
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications	06-08-24
SEED Therapeutics Inc. Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications	06-08-24

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BeyondSpring Inc.

Aandelen

BYSI

KYG108301006

Biotechnologie & Medisch Onderzoek

Andere talen

Filters